U
UroGen Pharma Ltd D
D
URGN
17.300
USD
0.62
(3.72%)
مغلق
حجم التداول
18,741
الربح لكل سهم
-3
العائد الربحي
-
P/E
-6
حجم السوق
800,369,484
العنوان: UroGen Pharma Ltd
القطاع: Healthcare
الصناعة: Biotechnology
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablationin forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.